FXN reactivation is an especially attractive therapeutic strategy in FRDA because the FXN coding sequence remains intact in the majority of patients, and the reactivated gene would likely benefit from the availability of endogenous regulatory elements. The gene discussed is FXN; the disease is Friedreich ataxia.